The Developmental Process of MK-3475 in Melanoma
Antoni Ribas, MD, PhD, discusses the development process of PD-1 antibody MK-3475 in melanoma.
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the development process of PD-1 antibody MK-3475 in melanoma.
Clinical Pearls
- MK-3475 has gone through phase I testing
- Physicians are eagerly awaiting data from a phase II clinical trial comparing chemotherapy to MK-3475 in patients who have previously received ipilimumab
- A trial studying two dosing regimens of MK-3475 compared to ipilimumab in frontline therapy for patients with metastatic melanoma is currently accruing
- MK-3475 is also being developed in other cancers, such as lung, bladder, and head and neck
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
